Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.26
QGEN's Cash-to-Debt is ranked lower than
77% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. QGEN: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
QGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.26  Med: 0.93 Max: N/A
Current: 0.26
Equity-to-Asset 0.60
QGEN's Equity-to-Asset is ranked higher than
54% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. QGEN: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
QGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.61 Max: 0.72
Current: 0.6
0.44
0.72
Interest Coverage 2.69
QGEN's Interest Coverage is ranked lower than
89% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. QGEN: 2.69 )
Ranked among companies with meaningful Interest Coverage only.
QGEN' s Interest Coverage Range Over the Past 10 Years
Min: 2.05  Med: 4.02 Max: 7.24
Current: 2.69
2.05
7.24
Piotroski F-Score: 6
Altman Z-Score: 3.73
Beneish M-Score: -2.81
WACC vs ROIC
6.92%
2.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 7.95
QGEN's Operating Margin % is ranked higher than
60% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. QGEN: 7.95 )
Ranked among companies with meaningful Operating Margin % only.
QGEN' s Operating Margin % Range Over the Past 10 Years
Min: 4.86  Med: 13.17 Max: 17.85
Current: 7.95
4.86
17.85
Net Margin % 6.17
QGEN's Net Margin % is ranked higher than
66% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. QGEN: 6.17 )
Ranked among companies with meaningful Net Margin % only.
QGEN' s Net Margin % Range Over the Past 10 Years
Min: 5.31  Med: 9.31 Max: 13.64
Current: 6.17
5.31
13.64
ROE % 3.21
QGEN's ROE % is ranked higher than
53% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. QGEN: 3.21 )
Ranked among companies with meaningful ROE % only.
QGEN' s ROE % Range Over the Past 10 Years
Min: 2.54  Med: 4.96 Max: 7.36
Current: 3.21
2.54
7.36
ROA % 1.99
QGEN's ROA % is ranked higher than
59% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. QGEN: 1.99 )
Ranked among companies with meaningful ROA % only.
QGEN' s ROA % Range Over the Past 10 Years
Min: 1.69  Med: 2.87 Max: 4.12
Current: 1.99
1.69
4.12
ROC (Joel Greenblatt) % 15.18
QGEN's ROC (Joel Greenblatt) % is ranked higher than
59% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. QGEN: 15.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
QGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.34  Med: 26.32 Max: 45.62
Current: 15.18
10.34
45.62
3-Year Revenue Growth Rate 1.40
QGEN's 3-Year Revenue Growth Rate is ranked lower than
61% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. QGEN: 1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
QGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1  Med: 12.1 Max: 36.2
Current: 1.4
1
36.2
3-Year EBITDA Growth Rate 5.40
QGEN's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. QGEN: 5.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
QGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8.2  Med: 14 Max: 40.7
Current: 5.4
-8.2
40.7
3-Year EPS without NRI Growth Rate 5.50
QGEN's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. QGEN: 5.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
QGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -21.5  Med: 11.6 Max: 44.2
Current: 5.5
-21.5
44.2
GuruFocus has detected 3 Warning Signs with Qiagen NV $QGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» QGEN's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

QGEN Guru Trades in Q2 2016

Paul Tudor Jones 16,200 sh (New)
Oakmark Intl Small Cap 2,323,000 sh (+60.10%)
Manning & Napier Advisors, Inc 6,111,364 sh (+31.68%)
George Soros Sold Out
Jim Simons Sold Out
PRIMECAP Management 20,128,325 sh (-1.78%)
» More
Q3 2016

QGEN Guru Trades in Q3 2016

Steven Cohen 294,400 sh (New)
Jim Simons 190,000 sh (New)
Paul Tudor Jones 17,000 sh (+4.94%)
PRIMECAP Management 19,473,847 sh (-3.25%)
Manning & Napier Advisors, Inc 5,295,154 sh (-13.36%)
Oakmark Intl Small Cap 1,666,000 sh (-28.28%)
» More
Q4 2016

QGEN Guru Trades in Q4 2016

Jim Simons 535,400 sh (+181.79%)
PRIMECAP Management 19,143,036 sh (-1.70%)
Paul Tudor Jones 16,373 sh (-3.69%)
Manning & Napier Advisors, Inc 4,832,166 sh (-8.74%)
Steven Cohen 260,400 sh (-11.55%)
Oakmark Intl Small Cap 1,158,000 sh (-27.82%)
» More
Q1 2017

QGEN Guru Trades in Q1 2017

Joel Greenblatt 120,947 sh (New)
John Hussman 122,200 sh (New)
Jim Simons 1,514,898 sh (+193.83%)
Steven Cohen 415,500 sh (+65.70%)
PRIMECAP Management 18,252,184 sh (-0.99%)
Manning & Napier Advisors, Inc 3,897,888 sh (-16.23%)
Paul Tudor Jones 9,358 sh (-40.65%)
» More
» Details

Insider Trades

Latest Guru Trades with QGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414 
Compare:NYSE:PKI, OTCPK:SUVPF, OTCPK:BMXMF, NYSE:BIO.B, NAS:INCR, OTCPK:ERFSF, NAS:DXCM, NAS:ICLR, OTCPK:CZMWF, NAS:PRAH, NYSE:CRL, NAS:VWR, NAS:BRKR, NYSE:ALR, OTCPK:SWTUY, NAS:PRXL, NAS:CPHD, NAS:EXAS, OTCPK:SSMXY, NAS:NEOG » details
Traded in other countries:QIA.Germany, QGEN.Switzerland, 0RLT.UK,
Headquarter Location:Netherlands
Qiagen NV provides sample and assay technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company operates in four segments: molecular diagnostics (50% of sales), academia (21%), pharmaceutical (20%), and applied testing (9%). Qiagen generates about 87% of its revenue from consumable sales and 13% from instrumentation. The Americas account for the largest portion of the firm's revenue (46%), followed by EMEA (34%) and Asia-Pacific (19%). Qiagen is headquartered in Venlo, Netherlands.

Ratios

vs
industry
vs
history
PE Ratio 91.39
QGEN's PE Ratio is ranked lower than
91% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. QGEN: 91.39 )
Ranked among companies with meaningful PE Ratio only.
QGEN' s PE Ratio Range Over the Past 10 Years
Min: 22.58  Med: 39.88 Max: 154.18
Current: 91.39
22.58
154.18
Forward PE Ratio 26.53
QGEN's Forward PE Ratio is ranked lower than
57% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. QGEN: 26.53 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 91.39
QGEN's PE Ratio without NRI is ranked lower than
91% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. QGEN: 91.39 )
Ranked among companies with meaningful PE Ratio without NRI only.
QGEN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.27  Med: 39.99 Max: 160.79
Current: 91.39
22.27
160.79
Price-to-Owner-Earnings 49.77
QGEN's Price-to-Owner-Earnings is ranked lower than
73% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. QGEN: 49.77 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
QGEN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 16.09  Med: 36.56 Max: 206.79
Current: 49.77
16.09
206.79
PB Ratio 3.08
QGEN's PB Ratio is ranked higher than
68% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. QGEN: 3.08 )
Ranked among companies with meaningful PB Ratio only.
QGEN' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.14 Max: 4.67
Current: 3.08
1.16
4.67
PS Ratio 5.66
QGEN's PS Ratio is ranked lower than
62% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. QGEN: 5.66 )
Ranked among companies with meaningful PS Ratio only.
QGEN' s PS Ratio Range Over the Past 10 Years
Min: 2.7  Med: 4.36 Max: 6.53
Current: 5.66
2.7
6.53
Price-to-Free-Cash-Flow 29.77
QGEN's Price-to-Free-Cash-Flow is ranked lower than
58% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. QGEN: 29.77 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
QGEN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 20  Med: 33.28 Max: 180.94
Current: 29.77
20
180.94
Price-to-Operating-Cash-Flow 21.57
QGEN's Price-to-Operating-Cash-Flow is ranked lower than
55% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. QGEN: 21.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
QGEN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.1  Med: 19.91 Max: 58.78
Current: 21.57
12.1
58.78
EV-to-EBIT 79.43
QGEN's EV-to-EBIT is ranked lower than
89% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. QGEN: 79.43 )
Ranked among companies with meaningful EV-to-EBIT only.
QGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: 17.5  Med: 34.55 Max: 93.8
Current: 79.43
17.5
93.8
EV-to-EBITDA 25.79
QGEN's EV-to-EBITDA is ranked lower than
71% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. QGEN: 25.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
QGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.6  Med: 16.6 Max: 31.7
Current: 25.79
9.6
31.7
PEG Ratio 48.11
QGEN's PEG Ratio is ranked lower than
100% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. QGEN: 48.11 )
Ranked among companies with meaningful PEG Ratio only.
QGEN' s PEG Ratio Range Over the Past 10 Years
Min: 1.67  Med: 3.18 Max: 6491
Current: 48.11
1.67
6491
Shiller PE Ratio 63.43
QGEN's Shiller PE Ratio is ranked lower than
73% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. QGEN: 63.43 )
Ranked among companies with meaningful Shiller PE Ratio only.
QGEN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 27.96  Med: 49.36 Max: 84.46
Current: 63.43
27.96
84.46
Current Ratio 2.79
QGEN's Current Ratio is ranked higher than
64% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. QGEN: 2.79 )
Ranked among companies with meaningful Current Ratio only.
QGEN' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 3.17 Max: 6.29
Current: 2.79
1.45
6.29
Quick Ratio 2.26
QGEN's Quick Ratio is ranked higher than
62% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. QGEN: 2.26 )
Ranked among companies with meaningful Quick Ratio only.
QGEN' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 2.59 Max: 5.75
Current: 2.26
1.18
5.75
Days Inventory 106.03
QGEN's Days Inventory is ranked lower than
61% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. QGEN: 106.03 )
Ranked among companies with meaningful Days Inventory only.
QGEN' s Days Inventory Range Over the Past 10 Years
Min: 98.81  Med: 112.97 Max: 128.65
Current: 106.03
98.81
128.65
Days Sales Outstanding 67.96
QGEN's Days Sales Outstanding is ranked lower than
64% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. QGEN: 67.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
QGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.73  Med: 72.41 Max: 78.03
Current: 67.96
63.73
78.03
Days Payable 33.10
QGEN's Days Payable is ranked lower than
63% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. QGEN: 33.10 )
Ranked among companies with meaningful Days Payable only.
QGEN' s Days Payable Range Over the Past 10 Years
Min: 35.1  Med: 45.07 Max: 68.16
Current: 33.1
35.1
68.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.10
QGEN's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. QGEN: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
QGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.5  Med: -1.1 Max: 0.3
Current: -0.1
-19.5
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.16
QGEN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
56% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. QGEN: 2.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
QGEN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.84 Max: 30.31
Current: 2.16
0.97
30.31
Price-to-Intrinsic-Value-DCF (Earnings Based) 8.55
QGEN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
100% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. QGEN: 8.55 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.29
QGEN's Price-to-Median-PS-Value is ranked lower than
58% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. QGEN: 1.29 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
QGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 1.11 Max: 7.77
Current: 1.29
0.52
7.77
Earnings Yield (Greenblatt) % 1.26
QGEN's Earnings Yield (Greenblatt) % is ranked lower than
54% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. QGEN: 1.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
QGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 2.9 Max: 5.7
Current: 1.26
1.1
5.7
Forward Rate of Return (Yacktman) % 5.56
QGEN's Forward Rate of Return (Yacktman) % is ranked lower than
56% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. QGEN: 5.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
QGEN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.1  Med: 14.4 Max: 19.6
Current: 5.56
-2.1
19.6

More Statistics

Revenue (TTM) (Mil) $1,347
EPS (TTM) $ 0.36
Beta1.13
Short Percentage of Float1.39%
52-Week Range $20.71 - 32.97
Shares Outstanding (Mil)227.66

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 1,410 1,514
EPS ($) 1.24 1.37
EPS without NRI ($) 1.24 1.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.16%
Dividends per Share ($)
» More Articles for QGEN

Headlines

Articles On GuruFocus.com
QIAGEN Reports Results for First Quarter 2017 May 02 2017 
QIAGEN Partners With Maccura to Localize and Commercialize GeneReader NGS System in China May 02 2017 
New Research Suggests Potential for Additional Clinical Utility of QIAGEN's QuantiFERON-TB Gold Plus Apr 12 2017 
QIAGEN Posts 2016 Annual Report on its Website Apr 06 2017 
QIAGEN N.V. to Report First Quarter 2017 Results Apr 06 2017 
QIAGEN's GeneReader NGS System Gains Further Validation in Oncology Research Applications With New I Apr 03 2017 
QIAGEN Expands Liquid Biopsy Pipeline with AR-V7 Test in Prostate Cancer Mar 31 2017 
QIAGEN Joins CANCER-ID Consortium for Liquid Biopsy Workflows Mar 31 2017 
QIAGEN Launches First FDA-cleared JAK2 Test for Certain Type of Leukemia Mar 31 2017 
David Herro's Oakmark International Small Cap Fund 4th Quarter Commentary Jan 08 2016 

More From Other Websites
Edited Transcript of QGEN earnings conference call or presentation 3-May-17 1:00pm GMT May 11 2017
Blog Coverage: INC Research Holdings Acquires Privately Held inVentiv Health May 11 2017
Qiagen Banks on Molecular Diagnostic amid Currency Woes May 08 2017
QIAGEN NV's Getting It Done May 04 2017
QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View May 03 2017
Qiagen beats Street 1Q forecasts May 02 2017
QIAGEN Reports Results for First Quarter 2017 May 02 2017
QIAGEN Partners With Maccura to Localize and Commercialize GeneReader NGS System in China May 02 2017
QIAGEN NV – Value Analysis (NASDAQ:QGEN) : April 26, 2017 Apr 26 2017
QIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : April 25, 2017 Apr 25 2017
The Top Gene-Sequencing Stock to Buy in 2017 Apr 20 2017
New Research Suggests Potential for Additional Clinical Utility of QIAGEN's QuantiFERON-TB Gold Plus Apr 12 2017
Qiagen (QGEN) Down 2.6% Since Earnings Report: Can It Rebound? Apr 12 2017
QIAGEN Posts 2016 Annual Report on its Website Apr 06 2017
QIAGEN N.V. to Report First Quarter 2017 Results Apr 06 2017
QIAGEN Releases Favorable GeneReader Results, Expands in NGS Apr 04 2017
QIAGEN's GeneReader NGS System Gains Further Validation in Oncology Research Applications With New... Apr 03 2017
QIAGEN Expands Liquid Biopsy Pipeline with AR-V7 Test in Prostate Cancer Mar 31 2017
QIAGEN Joins CANCER-ID Consortium for Liquid Biopsy Workflows Mar 30 2017
QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)